Key Takeaways PODD is seeing strong growth from its Omnipod 5 system, especially among Type 2 diabetes patients. Insulet expanded Omnipod 5 into 11 new international markets in early 2025. Macroeconomic headwinds and rising competition pose risks to PODD's growth and pricing power.Insulet Corporation’s (PODD) rapid commercial expansion of its Omnipod platform is poised to help it grow in the upcoming quarters. The rising adoption of Omnipod 5 also presents a promising growth opportunity. Meanwhile, advers ...

10 June 2025 | 10:02AM PDT Insulet Corp. (PODD): 46th Annual Global Healthcare Conference — Key Takeaways Presenters: Ana Maria Chadwick (EVP, CFO) Bottom Line: The company reiterated its core strategic priorities (driving increased penetration in Type 1s, ramping adoption in the Type 2 population, and expanding internationally) as well as achieving at least 100bps of annual operating margin expansion. PODD shares were underperforming the S&P 500 by ~250bps (at the time of this note), mainly as investors de ...

Insulet (PODD) FY Conference June 10, 2025 09:20 AM ET Speaker0 Well, good morning, everyone. We'll, we'll go ahead and get started here just to make a quick housekeeping announcement that, presentations are not open to members, of the press. With that, I'm very pleased to welcome Anna Maria Chadwick, Executive Vice President and Chief Financial Officer for Insulet. As with all these sessions, if there are questions, feel free to raise your hand, and we'll get a mic over to you so that people participating ...

Insulet Corporation (PODD) has witnessed strong momentum in the past year. Shares of the company have risen 78.5% compared with 7.3% growth of the industry during the same time frame. The S&P 500 Composite has increased 9.3%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Insulet develops, manufactures and markets the Omnipod System — an innovative, discreet and easy-to-use continuous insulin de ...

Insulet TodayPODDInsulet$314.46 -2.21 (-0.70%) 52-Week Range$160.19▼$323.00P/E Ratio54.31Price Target$306.53Add to WatchlistInsulet Corporation’s NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500. The medical device company, known for its innovative tubeless insulin pump system, saw its stock price climb by over 24% in the past five days. This jump in Insulet’s stock price has been driven by multiple catalyst’s including a r ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Insulet Corporation (PODD) reported first-quarter 2025 adjusted earnings per share (EPS) of $1.02, up 39.7% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 25.9%.GAAP EPS was 50 cents, down 32.4% from the year-ago quarter’s figure.PODD’s Q1 RevenuesRevenues totaled $569 million, which beat the Zacks Consensus Estimate by 4.9%. The top line jumped 28.8% year over year and 29.8% at constant exchange rate or CER. CER growth exceeded the company’s high end of the gui ...

Insulet Corporation PODD reported first-quarter adjusted earnings of $1.02 per share, beating the consensus of 80 cents.The automated insulin delivery technology maker reported sales of $569 million, up 28.8% year over year (29.8% in constant currency), beating the consensus of $543.4 million, exceeding the high end of the company’s guidance range of 25% in constant currency.Total Omnipod revenue reached $554.1 million, an increase of 28.0%, or 29.0% in constant currency.U.S. Omnipod revenue of $401.7 milli ...

Insulet (PODD) reported $569 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 28.8%. EPS of $1.02 for the same period compares to $0.73 a year ago.The reported revenue represents a surprise of +4.96% over the Zacks Consensus Estimate of $542.11 million. With the consensus EPS estimate being $0.81, the EPS surprise was +25.93%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...